Argenx's subcutaneous therapy meets late-stage goal in rare muscle disease, with subgroup miss

Argenx reported Monday that its subcutaneous drug Vyvgart Hytrulo achieved a primary endpoint in a Phase 3 trial covering a group of rare autoimmune myositis conditions. However, the treatment did not show benefit in a key patient subset, complicating the overall positive result. The company plans to discuss the data with regulators.